U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H19NOS.ClH
Molecular Weight 333.876
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DULOXETINE HYDROCHLORIDE

SMILES

Cl.CNCC[C@H](OC1=C2C=CC=CC2=CC=C1)C3=CC=CS3

InChI

InChIKey=BFFSMCNJSOPUAY-LMOVPXPDSA-N
InChI=1S/C18H19NOS.ClH/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16;/h2-10,13,17,19H,11-12H2,1H3;1H/t17-;/m0./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C18H19NOS
Molecular Weight 297.415
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Duloxetine (brand names Cymbalta, Yentreve, and in parts of Europe, Xeristar or Ariclaim) is indicated for the acute and maintenance treatment of major depressive disorder (MDD), as well as acute management of generalized anxiety disorder. Also used for the management of neuropathic pain associated with diabetic peripheral neuropathy, and fibromyalgia. Has been used in the management of moderate to severe stress urinary incontinence (SUI) in women. It is manufactured and marketed by Eli Lilly and Company. Duloxetine has not yet been FDA approved for stress urinary incontinence or for fibromyalgia. Duloxetine is a selective SNRI (selective serotonin-norepinephrine reuptake inhibitor). Duloxetine is a systemic drug therapy which affects the body as a whole. Known also under the code name LY248686, it is a potent dual reuptake inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE), possessing comparable affinities in binding to NE- and 5-HT transporter sites. It is a less potent inhibitor of dopamine reuptake.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
10.4 nM [IC50]
1.58 nM [IC50]
142.8 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Cymbalta
Primary
Cymbalta
Palliative
Cymbalta

Cmax

ValueDoseCo-administeredAnalytePopulation
55.88 μg/L
60 mg single, oral
DULOXETINE plasma
Homo sapiens
0.44 μg/L
15 mg single, oral
DULOXETINE plasma
Homo sapiens
31.82 μg/L
30 mg single, oral
DULOXETINE plasma
Homo sapiens
43.09 μg/L
30 mg 1 times / day multiple, oral
DULOXETINE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
1073.99 μg × h/L
60 mg single, oral
DULOXETINE plasma
Homo sapiens
175.39 μg × h/L
15 mg single, oral
DULOXETINE plasma
Homo sapiens
489.35 μg × h/L
30 mg single, oral
DULOXETINE plasma
Homo sapiens
840.26 μg × h/L
30 mg 1 times / day multiple, oral
DULOXETINE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
11.89 h
60 mg single, oral
DULOXETINE plasma
Homo sapiens
9.52 h
15 mg single, oral
DULOXETINE plasma
Homo sapiens
10.19 h
30 mg single, oral
DULOXETINE plasma
Homo sapiens
11.39 h
30 mg 1 times / day multiple, oral
DULOXETINE plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
DULOXETINE plasma
Homo sapiens

Doses

AEs

Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
Dosage for Treatment of Major Depressive Disorder Administer CYMBALTA (Duloxetine) at a total dose of 40 mg/day (given as 20 mg twice daily) to 60 mg/day (given either once daily or as 30 mg twice daily). For some patients, it may be desirable to start at 30 mg once daily for 1 week, to allow patients to adjust to the medication before increasing to 60 mg once daily.
Route of Administration: Oral
In Vitro Use Guide
The 50% inhibitory concentration (IC50) of duloxetine for the resting and inactivated wild-type hNav1.7 Na+ channel were 22.1+/-0.4 and 1.79+/-0.10 uM, respectively. Inhibitory effects were even more pronounced when using a mammalian cell line resulting in a 34 or 59% current decrease by 10 or 30 uM duloxetine, respectively.
Substance Class Chemical
Record UNII
9044SC542W
Record Status Validated (UNII)
Record Version